A randomized, open-label, comparative, multicenter trial to compare the effects on metabolic parameters of two NOMAC-E2 batches (pivotal phase III and commercial batch) and a monophasic COC containing 150 µg LNG and 30 µg EE (Phase III, Protocol No. P06447)

Published: 20-01-2010
Last updated: 10-08-2024

To compare the effects on the APC- (Activated Protein C) resistance ratio (ETP-[endogenous throbin potential] based) between the pivotal phase III NOMAC-E2 batch and a commercial NOMAC-E2 batchTo compare the effects on all other metabolic parameters...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON34789

Source
ToetsingOnline

Brief title
P06447

Condition

- Other condition

Synonym
contraception, preservatives

Health condition

anticonceptie

Research involving
Human

Sponsors and support

Primary sponsor: Schering-Plough
Source(s) of monetary or material Support: Farma-industrie: Schering-Plough

Intervention

Keyword: batches, comparison, contraception, hemodynamics

Outcome measures

Primary outcome

To compare the effects on the APC- (Activated Protein C) resistance ratio

(ETP-[endogenous throbin potential] based) between the pivotal phase III

NOMAC-E2 batch and a commercial NOMAC-E2 batch.

Secondary outcome

Compare effect on all other metabolic parameters of two NOMAC-E2 batches:

hemostasis parameters, lipids and SHBG

Compare effect on metabolic parameters (as descibed above) between the two

NOMAC-E2 batches and LNG-EE

General safety: decreased libido, depression/deppressed mood, altered mood,

headache, migraine, nausea, acne, breast pain, withdrawal bleeding irregular,

metrorrhagia, increased weight, routine lab parameters, vital signs, (serious)

adverse events

Study description

Background summary

Results from the Phase IIIa clinical development program showed that NOMAC-E2 has a robust contraceptive efficacy, a stable vaginal bleeding profile, good overall safety and tolerability, and less pronounced effects on metabolic parameters than seen with a traditional levonorgestrel-ethinylestradiol (LNG-EE) contraceptive pill.
After production of the two pivotal phase III batches, a number of changes within CMC development were made for the intended commercial production of NOMAC-E2. The purpose of this trial is to compare the safety data, specifically the effect on metabolic parameters, between a batch prepared using the commercial drug manufacturing process and one of the phase III pivotal clinical batches. The COC Microgynon®, containing 150 µg LNG and 30 µg EE, is used as an internal reference, because it is the standard to be included in hemostatic trials according to the relevant EMEA guideline. LNG-EE was also used in the previous metabolic trial with NOMAC-E2.

Study objective

To compare the effects on the APC- (Activated Protein C) resistance ratio (ETP-[endogenous throbin potential] based) between the pivotal phase III NOMAC-E2 batch and a commercial NOMAC-E2 batch

To compare the effects on all other metabolic parameters between the pivotal phase III NOMAC-E2 batch and a commercial NOMAC-E2 batch

To compare the effects on metabolic parameters between both NOMAC-E2 batches and a monophasic COC containing 150 µg LNG and 30 µg EE;

To evaluate general safety.

Study design

This is a randomized, open-label, parallel-group, multicenter, comparative trial of two NOMAC-E2 batches (pivotal phase III and commercial batch) and LNG-EE in healthy women.

Intervention

NOMAC-E2 pivotal phase III batch and commercial batch (2.5 mg NOMAC and 1.5 mg

E2) will be taken daily for three cycles of 28 days, each consisting of 24 NOMAC-E2 tablets and 4 placebo tablets.

LNG-EE (150 µg levonorgestrel-30µg ethynyl estradiol) will be taken daily for three cycles of 28 days, each consisting of 21 LNG-EE tablets and 7 placebo tablets.

Study burden and risks

At screening and at follow-up: physical, breast and gynecological examination, cervical smear (only at screening), blood sampling

Two months washout of contraceptives combined with condom use before start trial medication.

Home pregnancy test before first tablet intake

Daily diary entries from the day of first tablet intake

Visit 2, 3 blood sampling

Contacts

Public
Schering-Plough

Walmolen 1
3994 DL Houten
NL
Scientific
Schering-Plough

Walmolen 1
3994 DL Houten
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Each subject must be female and in good physical and mental health;
2. Each subject must be between 18 and 50 years (extremes included) of age at screening;
3. Each subject must have a body mass index between 17and 29 kg/m2 (extremes included)

Exclusion criteria

1. Any contraindication for contraceptive steroids;
2. An abnormal cervical smear (i.e. dysplasia, cervical intraepithelial neoplasia (CIN), squamous intraepithelial lesion (SIL), carcinoma in situ, invasive carcinoma) at screening;
3. Present use or use within 2 months prior to screening of any hormonal treatment including sex hormones (other than contraceptives), insulin, thyroid and corticosteroid hormones (with the exception of local dermatological use)
4. Present use or use within 2 months prior to starting trial medication of hepatic-enzyme inducing medications that may affect the bioavailability of sex steroids, lipid-lowering drugs, or anticoagulants.

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	15-03-2010
Enrollment:	200
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Microgynon 30
Generic name:	LNG-EE (levonorgestrel 150 µg-ethynyl oestradiol 30 µg)
Registration:	Yes - NL intended use
Product type:	Medicine
Brand name:	NOMAC-E2
Generic name:	2.5 mg NOMAC - 1.5 mg Oestradiol

Ethics review

Approved WMO Date:	20-01-2010
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	03-02-2010
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2009-017288-40-NL
CCMO	NL30926.056.10